---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-002558"
form_type: "8-K"
ticker: "OMER"
cik: "0001285819"
company_name: "OMEROS CORP"
filed_at: "2022-03-01T23:59:59+00:00"
generated_at: "2026-06-27T02:48:58.799301+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Omeros Q4 net income $280.6M including OMIDRIA gain; adjusted loss $0.37/share

## Summary
- Net income Q4 2021 $280.6M ($4.48/share) includes $184.6M non-cash gain from OMIDRIA royalty capitalization and $126M cash proceeds from sale.
- Adjusted Q4 net loss excluding OMIDRIA divestiture would have been $23.0M ($0.37/share) vs Q3 loss $22.7M ($0.36/share).
- Completed sale of OMIDRIA to Rayner Surgical on Dec 23, 2021 for $126M cash; Omeros retains 50% US royalty until $200M milestone then 30% thereafter.
- Received FDA Complete Response Letter for narsoplimab BLA in TA-TMA in Oct 2021; held Type A meeting in Feb 2022, awaiting FDA response.
- Cash and short-term investments $157.3M at Dec 31, 2021 plus $38.2M accounts receivable expected to be collected in Q1 2022.

## SEC filing metadata
- accession: 0001558370-22-002558
- form_type: 8-K
- ticker: OMER
- cik: 0001285819
- company_name: OMEROS CORP
- filed_at: 2022-03-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1285819/000155837022002558/0001558370-22-002558-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1285819/000155837022002558/omer-20220301x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-002558
- JSON: https://secwatch.observer/filing/0001558370-22-002558.json
- Plain text: https://secwatch.observer/filing/0001558370-22-002558.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.